Javad Aman | President & CSO
AbVacc Inc.

Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, infectious disease, and vaccine and immunotherapeutics development. He received his M.S. in Pharmacy from University of Frankfurt and Ph.D. in molecular immunology from University of Mainz, Germany. He performed his post-doctoral research at NIH and University of Virginia on signal transduction in immune cells. Dr. Aman has published over 130 papers ranging from basic research in immunology, signal transduction, to vaccine and antibody discovery in international scientific journals. He has established Integrated BioTherapeutics, Inc. (IBT) that combined a discovery CRO business and an R&D program focused on structure-based design and development of vaccines and monoclonal antibodies against emerging infectious diseases with a strong non-dilutive funding of over $115M and a strategic funding from Novo Holdings. IBT’s lead product, a vaccine for prevention of recurrent MRSA infection supported by CARB-X and NIH, is currently nearing Phase 1 clinical trial. Recently, Dr. Aman spun off the R&D programs of IBT into a new company named AbVacc focused on rational vaccine and monoclonal antibody design.